

Mark J. DeBoy

From: Jordi Ilario <jordi.ilario@fractus.com>
Sent: Friday, March 24, 2023 6:12 AM
To: Dermot O'Shea; Michael Pinczuk
Cc: Francisco Lopez; Melody Crinion; Farah Haddad
Subject: RE: ResMed | Letter to Fractus S.A.

Dear Mr. O'Shea and Mr. Pinczuk,

We must insist again on ResMed signing an NDA with Fractus before sharing claim charts. This is a long-standing company policy and follows licensing best practices. I don't understand ResMed's reluctance to sign such an NDA – it has no impact on ResMed, and there is no possible harm to ResMed from signing one, while there is potential harm to Fractus to proceed without an NDA.

Thanks,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Dermot O'Shea <doshea@taoglas.com>
Enviado el: jueves, 23 de marzo de 2023 16:52
Para: Jordi Ilario <jordi.ilario@fractus.com>; Michael Pinczuk <Michael.Pinczuk@resmed.com>
CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>; Farah Haddad <fhaddad@taoglas.com>
Asunto: Re: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

As previously requested by Taoglas and Resmed, we need to see the claims from Fractus in order to assist our customer Resmed answer you in a meaningful way. Without knowing what the claims are we cannot support Michael and his team.

Thanks Dermot

From: Jordi Ilario <jordi.ilario@fractus.com>
Date: Thursday, March 23, 2023 at 4:49 AM

To: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Cc: Francisco Lopez <francisco.lopez@fractus.com>, Melody Crinion <Melody.Crinion@resmed.com.au>, Dermot O'Shea <doshea@taoglas.com>, Farah Haddad <fhaddad@taoglas.com>
Subject: RE: ResMed | Letter to Fractus S.A.

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Pinczuk,

I hope this email finds you well.

We are still waiting for your answer to our proposed licensing framework below.

As indicated, we cannot accept discussing directly and solely with Taoglas. Still, they can be involved in technical discussions if and only if ResMed is present in said discussions.

Please let me tell you that we are progressing with several other companies in healthcare and other industries. In some instances, they are leading the discussion, and in others, they follow the framework proposed below, which follows licensing best practices.

I am looking forward to hearing from you.

Best regards,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Jordi Ilario
Enviado el: martes, 14 de febrero de 2023 10:48
Para: Michael Pinczuk <Michael.Pinczuk@resmed.com>
CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>; doshea@taoglas.com; fhaddad@taoglas.com
Asunto: RE: ResMed | Letter to Fractus S.A.

Dear Mr. Pinczuk,

Thank you for your email below. We understand your position and, as indicated before, can accept that Taoglas receives our technical information both written and orally.

Let me emphasize that ResMed uses Fractus's technology, taking full advantage of its integration through hardware and services; therefore, ResMed requires a license.

That being said, we would like to propose the following framework:

1. NDA executed between Fractus and ResMed
2. Fractus written approval of Taoglas as a receiving third party
3. Materials sent by Fractus to ResMed
4. ResMed shares materials with Taoglas
5. Technical discussions with ResMed (and representatives from Taoglas)
6. Business proposal to ResMed

We appreciate your time and attention to these issues and look forward to continuing this discussion.

Best regards,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Enviado el: jueves, 9 de febrero de 2023 4:33

Para: Jordi Ilario <jordi.ilario@fractus.com>; doshea@taoglas.com; fhaddad@taoglas.com

CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Asunto: RE: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

I noticed that you removed Mr. O'Shea and Ms. Haddad from the email string, so I am copying them back in. Just as you insist that Fractus does not agree to engage "directly and solely" with ResMed's supplier, ResMed equally insists that representatives from Taoglas be involved in our discussions going forward. Indeed, no one is suggesting that Fractus engage "solely" with Taoglas, but they do possess the relevant technical information and therefore should be involved in any discussions going forward. In fact, I expect they have questions and comments about your submissions to date, which you may find helpful. I will let them weigh in on that point, and then we can decide whether and how to proceed with our discussions. Thank you for respecting our wishes in this regard.

Kind regards,
Michael Pinczuk

From: Jordi Ilario <jordi.ilario@fractus.com>

Sent: Friday, 27 January 2023 11:17 PM

To: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Cc: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Subject: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Pinczuk,

Thank you for your email.

Let me reiterate that **Fractus does not agree that we should engage directly and solely with suppliers** and that ResMed is in the best position to take a license.

We must insist again on ResMed signing an NDA with Fractus before sharing claim charts. The second provision in said NDA defines a mechanism by which ResMed could disclose said claim charts with Taoglas.

Let me propose to have a video call with you to explain our position and make progress in this discussion. I understand that you are based in Australia. Would 6 p.m. or 7 p.m. your time (8 a.m. or 9 a.m. our time) work for you on any of the following dates?

- January 31st
- February 2nd
- February 7th
- February 9th

Best regards,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Enviado el: lunes, 23 de enero de 2023 3:00

Para: Jordi Ilario <jordi.ilario@fractus.com>; doshea@taoglas.com; fhaddad@taoglas.com

CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Asunto: RE: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

Thank you for your email of December 14, and thank you for confirming that Fractus is happy to include antenna suppliers in these discussions. To that end, I have copied representatives of ResMed's antenna supplier, Taoglas, on this email. If you do not already know them, Dermot O'Shea is the CEO of Taoglas and Farah Haddad is Associate General Counsel. They are both aware of our communications to date, and I expect one of them may have questions or comments for you. I may have a further response on your other points below once we hear from Taoglas. Thank you.

Kind regards,
Michael Pinczuk

From: Jordi Ilario <jordi.ilario@fractus.com>
Sent: Wednesday, 14 December 2022 10:45 PM
To: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Cc: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>
Subject: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Pinczuk,

My apologies for the delay in getting back to you. Fractus is not a large company, and we've been extremely busy preparing for the litigation against ADT and Vivint. Furthermore, we've been analyzing additional devices from ResMed, some of which we identified to you on November 9.

I'm sorry, but Fractus must insist on ResMed signing an NDA before Fractus will share claim charts. These charts contain Fractus's proprietary claim analysis, and if and until Fractus chooses to make them public, the company considers this information confidential. This is a long-standing company policy and is typical in licensing negotiations. I don't understand ResMed's reluctance to sign such an NDA – it has no impact on ResMed, and there is no possible harm to ResMed from signing one, while there is potential harm to Fractus to proceed without an NDA.

And as you've seen in the draft NDA I sent over, the second provision in said NDA defines a mechanism by which ResMed could disclose information to a third party after prior written approval of Fractus. We're happy to include antenna suppliers in these discussions but do not agree that Fractus should engage directly and solely with them. ResMed is in the best position to take a license, mainly as it is the entity that benefits the most from using Fractus's technology in its devices and through its services.

Lastly, concerning your question about what we mean by "any wireless device" it was already addressed in the third paragraph of our notice letter dated June 21, 2021, which I am here reproducing for your convenience.

Fractus's patents cover the technology that is ubiquitously employed by sellers, manufacturers, and users of wireless devices such as ResMed. Every wireless devices, including but not limited to healthcare products for sleep and/or respiratory care, that (i) incorporate a multiband and/or miniaturized wireless antenna, or integrate multiple antennas, that comprise the features recited in any of the Fractus's patents, (ii) are made, used, imported, sold, or offered for sale, or otherwise exploited by ResMed in a jurisdiction covered by any such patent, and (iii) are purchased or manufactured by a licensee of Fractus and not covered by the license to that supplier, requires a license under those patents.

I hope this answers all the points raised in your email. Looking forward to continuing the discussions. Best regards,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Enviado el: jueves, 8 de diciembre de 2022 3:52
Para: Jordi Ilario <jordi.ilario@fractus.com>

CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Asunto: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

This responds to your email of November 9, 2022, which I received after nearly 11 months of silence from you.

We would like to understand why ResMed is hearing from you again after such a lengthy delay. Can you please explain the months-long delay in responding to my most recent email from December of last year?

Second, your latest email and attachment provide no further information for ResMed and its supplier to evaluate. You acknowledge that claim charts are “made using ResMed’s products teardowns and a published patent language”—all publicly available information—but you claim that such claim charts somehow require an NDA because they contain “Fractus position, descriptions, and interpretations.” That is not a valid reason for refusing to share claim charts with ResMed and its supplier without an NDA. Indeed, your email refers to complaints filed against ADT LLC and Vivint, Inc. in federal district court in the United States, and both of those public complaints contain relatively detailed limitation-by-limitation analysis of alleged infringement. Those complaints, in fact, contain the level of detail we would expect to see in claim charts supplied by Fractus to ResMed and its supplier. It makes no sense to us that Fractus is able to share its analysis of alleged infringement publicly in some circumstances but not with ResMed. Thus (and I am needing to repeat myself again), if Fractus continue to refuse to supply claim charts to ResMed and its supplier without an NDA, we do not see any basis to continue this discussion.

Third, your email refers to a “direct discussion between licensee and licensor,” but once again you fail to explain why Fractus cannot (or will not) engage with our supplier of wireless antennas in these discussions. We once again ask that you explain why you cannot engage in a direct discussion with the company that supplies the relevant technology to ResMed. To be clear, we must insist that our supplier be at least involved in any further discussions, once we have claim charts from you to evaluate.

Finally, I asked in my prior email nearly a year ago for Fractus to explain what it means by “any wireless device.” Your email is silent on that point, so we again ask for Fractus to explain what precisely it believes its patents cover.

Please respond individually to each of the points raised above. We look forward to hearing from you.

Kind regards,
Michael Pinczuk

From: Jordi Ilario <jordi.ilario@fractus.com>

Sent: Wednesday, 9 November 2022 1:51 AM

To: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Cc: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Subject: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Pinczuk,

I hope that you are doing well. Let me congratulate you since ResMed has had extraordinary results in the past year and has become the market leader.

I am reaching out to continue our discussion. Fractus has identified additional infringing products and additional patents and claims owned by Fractus that ResMed infringes, as shown in Exhibit I.A to this letter which supplements Exhibit I to the June 21, 2021 letter, but Fractus does not withdraw any of the statements made in Exhibit I.

Regarding your email below, we firmly believe that a direct discussion between licensee and licensor is the best way to progress towards a license agreement. We can help you understand the technology, ResMed's current use of our patents by sending you claim charts, but to do that, we need an NDA. We can move forward with Fractus NDA, a unilateral NDA just protecting the information shared by Fractus, or use your standard NDA.

Let me emphasize that although claim charts are made using ResMed's products teardowns and a published patent language, they contain Fractus position, descriptions, and interpretations and need to be protected by an NDA.

Recently, Fractus has filed two complaints in the Eastern District of Texas against ADT, LLC and Vivint, Inc. for using its technology without authorization. Fractus is represented by Susman Godfrey L.L.P.

Fractus strongly prefers to resolve intellectual property infringement through negotiation and invites again ResMed to engage in meaningful discussions to determine where the companies' interests align.

Thank you again for your time and attention to this important matter. I look forward to speaking with you soon.

Yours sincerely,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Enviado el: lunes, 20 de diciembre de 2021 1:24

Para: Jordi Ilario | Fractus <jordi.ilario@fractus.com>

CC: 'Francisco Lopez' <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>

Asunto: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

This responds to your email of October 27, 2021.

First, your email refers to a "direct discussion between licensee and licensor." We have now pointed out multiple times that the entity to engage with is our supplier of wireless antennas. Please explain why you cannot engage in a direct discussion with the company that supplies the technology to which your June 21, 2021 letter refers.

Second, your email refers to "any wireless device," but your original letter to ResMed was limited to "multiband and/or miniaturized wireless antennas." Please explain what you mean by "any wireless device," if you intended to refer to a broader set of devices than the wireless antennas identified in your original letter.

Third, we continue to believe an NDA is unnecessary at this juncture in order to provide claim charts to ResMed and its supplier. As we have explained, the information in those claim charts undoubtedly will be information that originates

from ResMed, from its supplier, or both. If you are unable to supply claim charts to ResMed and its supplier without an NDA, we do not see any basis to continue this discussion.

Kind regards,
Michael Pinczuk

From: Jordi Ilario | Fractus <jordi.ilario@fractus.com>
Sent: Wednesday, 27 October 2021 8:40 PM
To: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Cc: 'Francisco Lopez' <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>
Subject: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Pinczuk,

Thank you for your response below. Please note that as indicated in our letter dated June 21, 2021, any wireless device that is made, used, imported, sold, or offered for sale, or otherwise exploited by ResMed requires a license.

In our experience, a direct discussion between licensee and licensor is the best way to progress towards a license agreement. That being said, I propose signing an NDA between ResMed and Fractus to protect the information shared. I am attaching our standard NDA again.

Best regards,



Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Enviado el: miércoles, 15 de septiembre de 2021 5:12
Para: Jordi Ilario | Fractus <jordi.ilario@fractus.com>
CC: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>
Asunto: RE: [External] RE: ResMed | Letter to Fractus S.A.

Dear Mr. Ilario,

Thank you for your email below. It is disappointing that Fractus is choosing to target ResMed's resources at such a crucial time in our company's history, given the continuing (and worsening in many parts of the world) global pandemic. This is especially true because Fractus knows that the technology it is pointing to is supplied to ResMed by third parties with whom Fractus has apparently chosen not to engage.

I note there is no need for an NDA at this juncture, because all of the information in those claim charts undoubtedly will be information that originates from ResMed, from its supplier, or both.

As such, please direct the claim charts and future correspondence to our supplier Taoglas, via email to legalnotices@taoglas.com with a copy to Autumn Moody amoody@taoglas.com.

Kind regards,
Michael Pinczuk

From: Michael Pinczuk <Michael.Pinczuk@resmed.com>
Sent: Tuesday, 10 August 2021 9:19 AM
To: Jordi Ilario | Fractus <jordi.ilario@fractus.com>
Cc: Francisco Lopez <francisco.lopez@fractus.com>; Melody Crinion <Melody.Crinion@resmed.com.au>
Subject: Re: [External] RE: ResMed | Letter to Fractus S.A.

Hi Jordi, thanks for your note. I am currently on leave and will respond on my return.

Kind regards,
Michael Pinczuk

On 6 Aug 2021, at 3:22 am, Jordi Ilario | Fractus <jordi.ilario@fractus.com> wrote:

Dear Mr. Pinczuk,

Thank you very much for your email dated July 26, 2021, to Mr. Bonet, which has been passed to me for handling.

Fractus recognizes the vital importance of ResMed in providing products for sleep and respiratory care, especially in light of the current COVID-19 pandemic. That being said, and as indicated in our letter dated June 21, 2021, we have analyzed some of ResMed's products and determined that ResMed infringes Fractus's patents.

We are happy to provide claim charts regarding the products identified in Exhibit I to our letter dated June 21, 2021. Please find enclosed our standard NDA to protect the exchange of information.

Fractus believes that a direct discussion between licensee and licensor is the most effective way to progress towards a license agreement. We are looking forward to making progress with you.

Best regards,

<image008.png>

Jordi Ilario
COO and Vice President, Licensing

Alcalde Barnils, 64-68, Modul A, 3a pl
08174 – Sant Cugat del Valles
www.fractus.com
Tel: +34.93.544.2690

This email message contains information that may be confidential, be protected by client-attorney or other applicable privileges, or constitute non-public information. If you are not the intended recipient of this message, please notify the sender and then delete it. Use, dissemination, distribution, or reproduction of this message by unintended recipients is not authorized and may be unlawful.

De: Melody Crinion <Melody.Crinion@resmed.com.au>

Enviado el: lunes, 26 de julio de 2021 8:09

Para: ruben.bonet@fractus.com

CC: Michael Pinczuk <Michael.Pinczuk@resmed.com>

Asunto: ResMed | Letter to Fractus S.A.

Dear Mr. Bonet,

Please see attached letter, the original will be sent via courier.

Kind regards
Melody Crinion

Sent on behalf of Michael Pinczuk

Melody Crinion

Paralegal - Intellectual Property

ResMed 1 Elizabeth Macarthur Drive, Bella Vista NSW 2153,
Australia

D +61 481 917 914

<image002.png>

E melody.crinion@resmed.com.au **W** ResMed.com

<image003.jpg>

<image004.jpg>

<image005.jpg>

<image006.jpg>

<image003.jpg>

<image005.jpg>

<image001.jpg> <image006.jpg>

<image007.jpg>

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or

legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on +61 2 8884 1000 Sydney, Australia.

Caution: This email originated outside of ResMed's email system. Do not click on links or attachments unless you recognize the sender and know the content is safe.

<Fractus Standard NDA_2021.docx>

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on 1 (800) 424-0737 USA.

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on 1 (800) 424-0737 USA.

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on 1 (800) 424-0737 USA.

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on 1 (800) 424-0737 USA.

Caution: This email originated outside of ResMed's email system. Do not click on links or attachments unless you recognize the sender and know the content is safe.

Warning: Copyright ResMed. Where the contents of this email and/or attachment includes materials prepared by ResMed, the use of those materials is subject exclusively to the conditions of engagement between ResMed and the intended recipient.

This communication is confidential and may contain legally privileged information. By the use of email over the Internet or other communication systems, ResMed is not waiving either confidentiality of, or legal privilege in, the content of the email and of any attachments. If the recipient of this message is not the intended addressee, please call ResMed immediately on 1 (800) 424-0737 USA.

CAUTION: This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this e-mail in error, please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute, or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient, you are notified that disclosing, copying, distributing, or taking any action in reliance on the contents of this information is strictly prohibited.